Skip to main content

Development of Staging Guidelines for Metastatic Breast Cancer: Which method is best?

Conferences
Plichta, JK; Rey, V; Blasingame, M; Luo, S; Thomas, SM
Published in: CLINICAL CANCER RESEARCH
February 17, 2026

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

CLINICAL CANCER RESEARCH

EISSN

1557-3265

ISSN

1078-0432

Publication Date

February 17, 2026

Volume

32

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Plichta, J. K., Rey, V., Blasingame, M., Luo, S., & Thomas, S. M. (2026). Development of Staging Guidelines for Metastatic Breast Cancer: Which method is best? In CLINICAL CANCER RESEARCH (Vol. 32).
Plichta, J. K., V. Rey, M. Blasingame, S. Luo, and S. M. Thomas. “Development of Staging Guidelines for Metastatic Breast Cancer: Which method is best?” In CLINICAL CANCER RESEARCH, Vol. 32, 2026.
Plichta JK, Rey V, Blasingame M, Luo S, Thomas SM. Development of Staging Guidelines for Metastatic Breast Cancer: Which method is best? In: CLINICAL CANCER RESEARCH. 2026.
Plichta, J. K., et al. “Development of Staging Guidelines for Metastatic Breast Cancer: Which method is best?CLINICAL CANCER RESEARCH, vol. 32, 2026.
Plichta JK, Rey V, Blasingame M, Luo S, Thomas SM. Development of Staging Guidelines for Metastatic Breast Cancer: Which method is best? CLINICAL CANCER RESEARCH. 2026.

Published In

CLINICAL CANCER RESEARCH

EISSN

1557-3265

ISSN

1078-0432

Publication Date

February 17, 2026

Volume

32

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences